Chen EY, Mahurkar-Joshi S, Liu C, Jaffe N, Labus JS, Dong TS, et al
The ability to address multiple health concerns with a single medication could simplify treatment regimens and improve patient outcomes
Accordingly, and in line with currently ongoing trials in HFpEF (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not
During sign-up, you will have to provide personal information, such as your medical history
What is unknown about GLP-1 drug use is as important as what is known
6.3 HCC Preliminary evidence suggests that GLP-1RAs may provide protective effects against HCC development